Eevia Health has been repositioning for global growth after losing a significant portion of its revenue from a major U.S. customer in 2023. The company is now working with several global nutraceutical brands and focusing on polyphenol-rich botanical extracts from Arctic plants. Eevia plans to close its manufacturing site in Finland due to a lack of public and non-dilutive funding and move production to BIOTEP in Tromsø, Norway, which offers advanced facilities and reduced costs. This move will impact up to eight employees in Finland, but Eevia will maintain its core functions in sales, R&D, and market development. The partnership with Nofima and BIOTEP will allow Eevia to optimize production and innovate without major upfront investments. Eevia aims to improve profitability and sustainability by converting side-stream materials into sellable products. The company is focused on restoring profitability and cash flow through strategic moves and partnerships. Eevia Health specializes in sustainable bioactive extracts from Nordic plants and berries, offering ingredients for gut health, cellular protection, and inflammation, and operates a modern production facility in Finland.

Eevia Health Plc, a company specializing in sustainable bioactive extracts, is facing ongoing liquidity challenges. Despite reducing operating costs and recovering some revenue after losing a major customer in July 2023, the company continues to struggle financially, operating with negative EBITDA. Eevia has conducted two rights issues, raising nearly €2 million in equity, but has been unable to secure non-dilutive funding from Finnish institutions, with several funding applications rejected. The management has been working on a turnaround plan involving new sales contracts and cost optimization, but the lack of financial backing has led to some investors withdrawing support. Eevia plans to shift R&D and production to more supportive regions to address funding gaps. The company is implementing an urgent plan to generate cash by selling inventory, reducing costs, and seeking a bridge loan. Eevia sees commercial opportunities through recent sales contracts but needs capital to realize them. The company aims to reorganize privately, avoiding public restructuring. Audit processes have been delayed due to financial uncertainties, and asset valuations are being conservatively adjusted. Despite these challenges, Eevia remains committed to protecting shareholders and creditors and continues to explore strategic options.

Vitafoods är en viktig mötesplats för nutraceutisk industri, med över 21,500 deltagare från mer än 160 länder. I år hölls evenemanget i Barcelona. Eevia lanserade sin nya produkt FENO-ARONIA™ 50 Organic, en hälsosam ingrediens med hög koncentration av bioaktiva polyfenoler, vilket genererade stort intresse och två snabba beställningar. Eevia ingick också ett långsiktigt avtal om FENO-CHAGA™ Organic med en strategisk partner. Företaget överväger ett råmaterialpartnerskap och fick stöd från styrelseledamoten Dr. Diane Clayton under evenemanget. Eevia Health Plc, grundat 2017, tillverkar organiskt certifierade växtextrakt från finska och svenska skogar. Produkterna säljs globalt som ingredienser till kosttillskott och livsmedelsmärken. Eevia är listat på Spotlight Stock Market i Sverige sedan juni 2021.

The Corporation, a leader in specialty ingredients for health, beauty, and wellness industries, has entered a new global supply agreement with Eevia after a 20-month collaboration. This partnership, which began with a non-disclosure agreement in October 2023, involved feasibility studies and trials confirming the safety and readiness of Feno-Chaga™ Organic, an extract from Chaga mushrooms. The five-year agreement includes minimum sales volumes and quality standards, with the Partner responsible for marketing and sales. Eevia will focus on manufacturing while the Partner handles clinical research and market expansion. This arrangement allows Eevia to grow revenue and allocate resources to other products. For more details, contact Stein Ulve, CEO of Eevia Health.

In the first quarter of 2025, Eevia reported a 78% increase in net sales revenues compared to the previous quarter, although there was a 30% decrease compared to the same quarter in 2024. The company has seen a positive underlying sales trend over the past six quarters and has developed a new product category called "High-Strength Extracts." Gross profit increased by 87% from the previous quarter, with a gross margin of 59%. Management focused on reducing fixed costs, resulting in decreased personnel and operating expenses. However, EBITDA was negative at KEUR -166, and the net result after tax was KEUR -499. Cash flow from operations was negative, partly due to reduced payables. A rights issue was completed to address a funding gap, but further funding measures are being prepared. Inventory write-downs for 2024 were made after the Year-End Report. Plans for a new manufacturing facility in Finland are on hold, with a focus on improving the existing facility in Kauhajoki. The divestment of IP related to Retinari™ was completed, and Marinus Blåbjerg Sørensen was elected to the Board.

Eevia Health Plc, based in Seinäjoki, Finland, has announced changes to its financial calendar. The Interim Report for Q1-2025 will now be published on May 20, instead of May 18, to avoid a Sunday release and to ensure Board approval beforehand. The statutory financial statements and auditor’s report will be released on June 10, 2025. The Annual General Meeting will take place on June 27, 2025, with the notice being published on June 10. Eevia Health, founded in 2017, produces bioactive compounds from plant materials, primarily wild-harvested from Finnish and Swedish forests. The company is known for its organically certified extracts and operates a production facility in Finland. Eevia is listed on the Spotlight Stock Market in Sweden. For more information, contact CEO Stein Ulve or visit their website.

Eevia Health Plc has launched FENO-ARONIA™ 50 Organic, a new extract made from organic Aronia berries, known for its purity and high concentration of anthocyanins and polyphenols. The product, produced in Finland, is claimed to have health benefits related to blood sugar, cholesterol, and blood pressure management. It is highly water-soluble, low in sugars, and cost-efficient due to its concentrated formulation. Eevia Health, established in 2017, produces bioactive compounds from primarily wild-harvested plants in Finland and Sweden, focusing on sustainability and transparency. The company is listed on the Spotlight Stock Market in Sweden.

Eevia Health has formed a partnership with a global nutraceutical company based in Canada, which is part of a larger multinational group. This collaboration follows the relaunch of FENO-SAMBUCUS™ 30, a high-strength, excipient-free elderberry extract. The product is noted for its double potency compared to other market options, offering benefits like reduced dosage volume and cost efficiency. It is produced using sustainable methods at Eevia's Finnish facility and has a low carbon footprint. The partnership aims to leverage the Canadian company's strong sales and marketing capabilities to expand Eevia's global reach in the immune health sector. Eevia Health, founded in 2017 and listed on the Spotlight Stock Market in Sweden, specializes in bioactive compounds from plant materials, primarily sourced from Finnish and Swedish forests.

Eevia Health is progressing in its product development with plans to start clinical studies for MaxBIOME™ and ProRENIS™, targeting gut and kidney health, respectively. These products are aimed at the growing global nutraceutical market, with a goal to launch by 2026. Eevia has signed Letters of Intent with two established nutraceutical companies, indicating a mutual interest in exploring commercial agreements and market strategies after clinical trials. Erik Eide, Eevia's Commercial Director, highlighted the strong interest from these potential partners, which supports the commercial potential of Eevia's products. Eevia Health, founded in 2017, produces bioactive compounds from sustainably harvested plant materials, primarily from Finnish and Swedish forests. The company is committed to environmentally friendly production and operates a facility in Finland. Eevia's shares are listed on the Spotlight Stock Market in Sweden. For more information, contact CEO Stein Ulve or visit their website.

Eevia Health Plc received an accelerated order for their organic elderberry extract, FENO-SAMBUCUS™ 7 ORGANIC, from a U.S. nutraceutical brand due to higher-than-expected demand. The extract, known for supporting immune and general wellness, is ready for immediate delivery, benefiting Eevia's cash flow. Eevia, founded in 2017, produces 100% organically certified plant extracts from Finnish and Swedish forests, focusing on gut and related health. The company operates a sustainable production facility in Finland and is listed on the Spotlight Stock Market in Sweden.

Several major U.S. companies are urgently seeking alternative sources for plant-based ingredients due to high import tariffs on Chinese products. Eevia Health has received multiple requests from U.S. buyers looking for European-origin supplies, as tariffs are lower. Although the U.S. tariffs are seen as temporary, their uncertain duration has led to increased purchasing and procurement strategies. Eevia sees potential short-term sales opportunities, especially in low-concentrate extracts and powders, and is assessing logistics and raw material availability to handle larger orders. This situation could enhance Eevia’s position as a reliable European supplier and underscores the importance of regional supply chain resilience. Eevia Health, founded in 2017, produces organic plant extracts from Finnish and Swedish forests, focusing on health-related products. The company operates a green-chemistry facility in Finland and is listed on the Spotlight Stock Market in Sweden.

Denna vecka mottog Eevia Health Plc nya försäljningsorder på totalt 50 000 euro. Dessa inkluderar 28 000 euro för Feno-Chaga™ Organic SKUs, 11 000 euro för Feno-Myrtillus® Organic SKUs och 11 000 euro för andra högkoncentrerade polyfenolextrakt. Alla beställda produkter finns i lager, vilket möjliggör omedelbar leverans och förbättrar kassaflödet. Orderna visar på en fortsatt efterfrågetillväxt för Eevias premiumorganiska bioaktiva ingredienser på strategiska marknader och bekräftar företagets produktpositionering inom den globala nutraceutical-sektorn. Eevia Health Plc grundades i mars 2017 och fokuserar på att hantera globala hälsoutmaningar med bioaktiva föreningar från förnybara växtmaterial. Företaget tillverkar 100% ekologiskt certifierade växtextrakt, främst från skogar i Finland och Sverige. Dessa säljs B2B som ingredienser till kosttillskott och livsmedelsvarumärken globalt. Eevia utvecklar även högvärdiga livsmedelsingredienser och biomaterial som gynnar människors hälsa. Företaget driver en miljövänlig produktionsanläggning i Finland och noterades på Spotlight Stock Market i Sverige i juni 2021 under kortnamnet EEVIA.